Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

Exclusion Criteria

• •1. Subject has an active herpes zoster lesion on the face, head, neck, genital or rectal areas.
• •2. Subject has rash limited to trunk and limbs, with a total surface area greater than 300 cm2.
• •3. Subject has a known history of allergic reaction, hypersensitivity, or clinically significant intolerance to lidocaine, ingredients of the study drug, or local anesthetics of the amide type.
• •4. Subject has target skin area (allodynic area and surrounding skin) that is not intact, is inflamed, or in the opinion of the Principal Investigator, consistent with rash due to acute herpes zoster.
• •5. Subject has any other form of pain that was not discernible from herpes zoster (shingles) allodynia.
• •6. Subject is taking Class I antiarrhythmic drugs (e.g., tocainide, mexiletine), or medications that could interact with the study drug or interfere with its evaluation.